233 related articles for article (PubMed ID: 16106027)
1. Cetuximab therapy and symptomatic hypomagnesemia.
Schrag D; Chung KY; Flombaum C; Saltz L
J Natl Cancer Inst; 2005 Aug; 97(16):1221-4. PubMed ID: 16106027
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Fakih MG; Wilding G; Lombardo J
Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
[TBL] [Abstract][Full Text] [Related]
3. Re: Cetuximab therapy and symptomatic hypomagnesemia.
Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA
J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039
[No Abstract] [Full Text] [Related]
4. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
Stintzing S; Fischhaber D; Mook C; Modest DP; Giessen C; Schulz C; Haas M; Boeck S; Michl M; Stemmler J; Laubender RP; Heinemann V
Anticancer Drugs; 2013 Oct; 24(9):969-74. PubMed ID: 23863616
[TBL] [Abstract][Full Text] [Related]
5. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
Tejpar S; Piessevaux H; Claes K; Piront P; Hoenderop JG; Verslype C; Van Cutsem E
Lancet Oncol; 2007 May; 8(5):387-94. PubMed ID: 17466895
[TBL] [Abstract][Full Text] [Related]
6. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
9. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab.
Melichar B; Králíčková P; Hyšpler R; Kalábová H; Cerman J; Holečková P; Studentová H; Malířová E
Hepatogastroenterology; 2012; 59(114):366-71. PubMed ID: 22353500
[TBL] [Abstract][Full Text] [Related]
10. Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.
Perrin C; Fabre C; Raoul JL; Boucher E
Acta Oncol; 2006; 45(8):1135-6. PubMed ID: 17118852
[No Abstract] [Full Text] [Related]
11. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S9-19. PubMed ID: 21843103
[TBL] [Abstract][Full Text] [Related]
12. Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.
do Pazo-Oubiña F; Estefanell-Tejero A; Riu-Viladoms G; Anglada-Martínez H; Molas-Ferrer G; Creus-Baró N
J Clin Pharm Ther; 2013 Apr; 38(2):101-3. PubMed ID: 23278401
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR monoclonal antibody-induced hypomagnesaemia.
Fakih M
Lancet Oncol; 2007 May; 8(5):366-7. PubMed ID: 17466890
[No Abstract] [Full Text] [Related]
15. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
16. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Vincenzi B; Santini D; Galluzzo S; Russo A; Fulfaro F; Silletta M; Battistoni F; Rocci L; Zobel BB; Adamo V; Dicuonzo G; Tonini G
Clin Cancer Res; 2008 Jul; 14(13):4219-24. PubMed ID: 18594003
[TBL] [Abstract][Full Text] [Related]
17. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
18. [Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab].
Demizu M; Ueda H; Osawa M; Chihara S; Igarashi T; Yano K; Kimura F; Tanaka N; Hiratsuka M
Gan To Kagaku Ryoho; 2013 Jul; 40(7):897-900. PubMed ID: 23863731
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. [Cetuximab].
Takiuchi H
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]